Article focus {#section5-2046-3758.85.BJR-2018-0280.R3}
=============

-   This study aimed to evaluate the efficacy of ethylenediaminetetraacetic acid (EDTA) irrigation solution in the eradication of drug-resistant bacteria in a rat wound infection model.

Key messages {#section6-2046-3758.85.BJR-2018-0280.R3}
============

-   EDTA solution did not negatively affect wound healing compared with normal saline.

-   Our study showed the superiority of EDTA solution over commonly used irrigation solutions in the eradication of drug-resistant pathogens from infected wounds.

Strengths and limitations {#section7-2046-3758.85.BJR-2018-0280.R3}
=========================

-   Our study used seven of the most commonly found bacterial species in fracture-related infections. The study was adequately powered (up to 50 rats for each group).

-   Our study used an *in vivo* rat model of wound infection; the findings presented here would still require validation in a human study prior to clinical application.

Introduction {#section8-2046-3758.85.BJR-2018-0280.R3}
============

Wound infections remain a challenging global surgical problem, despite advances in operative techniques and the widespread use of systemic antibiotic prophylaxis.^[@bibr1-2046-3758.85.BJR-2018-0280.R3]^ The management of wound infection requires thorough irrigation and debridement to eliminate pathogens and promote healing.^[@bibr2-2046-3758.85.BJR-2018-0280.R3],[@bibr3-2046-3758.85.BJR-2018-0280.R3]^ The main purpose of these procedures is to reduce the pathogen load in the wound. The potential advantages of irrigation include physical removal, destruction, and creating a hostile environment for contaminated bacteria. However, the optimal irrigation solution to use in these procedures is still unknown.^[@bibr1-2046-3758.85.BJR-2018-0280.R3],[@bibr4-2046-3758.85.BJR-2018-0280.R3]-[@bibr9-2046-3758.85.BJR-2018-0280.R3]^

Studies have demonstrated enhanced bacteria removal with surfactants compared with normal saline (0.9%) (NS).^[@bibr10-2046-3758.85.BJR-2018-0280.R3]-[@bibr13-2046-3758.85.BJR-2018-0280.R3]^ However, surfactants cause toxicity to host tissues and can adversely affect healing.^[@bibr14-2046-3758.85.BJR-2018-0280.R3],[@bibr15-2046-3758.85.BJR-2018-0280.R3]^ Likewise, there is little evidence to support the effectiveness of bactericidal solutions, including bacitracin solution and benzalkonium chloride, as wound irrigation fluids. Additionally, there are concerns that associated toxicity to the host tissue with subsequent necrosis may in fact increase the risk of bacterial infection.^[@bibr16-2046-3758.85.BJR-2018-0280.R3]^ The clinical use of such solutions is therefore not recommended.^[@bibr17-2046-3758.85.BJR-2018-0280.R3]^ For those wounds with bacteria that are difficult to eradicate (e.g. prosthetic joint infection (PJI)), creating a pathogen-hostile environment might be effective by using chemicals including antibiotics and acetic acid.^[@bibr18-2046-3758.85.BJR-2018-0280.R3]-[@bibr21-2046-3758.85.BJR-2018-0280.R3]^ However, the effectiveness and safety profile of these solutions are yet to be definitively established in humans.^[@bibr22-2046-3758.85.BJR-2018-0280.R3]-[@bibr24-2046-3758.85.BJR-2018-0280.R3]^

A recent study demonstrated that NS supplemented with ethylenediaminetetraacetic acid (EDTA) increased the efficacy of removing *Staphylococcus aureus* (*S. aureus*) and *Escherichia coli* (*E. coli*), and caused no additional toxicity in an open fracture model, compared with NS alone.^[@bibr25-2046-3758.85.BJR-2018-0280.R3]^ Bacterial adhesion requires adhesins, which are molecules located on the surface of pathogenic bacteria, to interact with host tissues.^[@bibr26-2046-3758.85.BJR-2018-0280.R3]^ Most of the bacterial adhesins are cell-surface proteins that require the presence of ions including calcium, zinc, and magnesium to function.^[@bibr27-2046-3758.85.BJR-2018-0280.R3]-[@bibr29-2046-3758.85.BJR-2018-0280.R3]^ EDTA could competitively chelate these ions including calcium, zinc, and magnesium to form a complex and thereby remove bacteria.^[@bibr30-2046-3758.85.BJR-2018-0280.R3],[@bibr31-2046-3758.85.BJR-2018-0280.R3]^ However, further study with other bacterial strains and species, especially drug-resistant ones, is still needed in order to determine the ability of EDTA to disrupt adhesion in different kinds of bacterial infections.^[@bibr32-2046-3758.85.BJR-2018-0280.R3]^

Materials and Methods {#section9-2046-3758.85.BJR-2018-0280.R3}
=====================

Ethical approval {#section10-2046-3758.85.BJR-2018-0280.R3}
----------------

The study and all protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Beijing Changping Hospital (Beijing, China). All study methods were in accordance with China's regulations on animal study.

Bacterial culture and preparation of inoculum {#section11-2046-3758.85.BJR-2018-0280.R3}
---------------------------------------------

We chose seven species of bacteria that were responsible for over 90% of wound infections.^[@bibr33-2046-3758.85.BJR-2018-0280.R3]^ The following strains of bacteria were obtained from the American Type Culture Collection (ATCC): methicillin-resistant *Staphylococcus aureus* (MRSA), BAA-1747; extended spectrum beta-lactamase-producing *E. coli* (ESBL-EC), BAA-196; multidrug-resistant *Pseudomonas aeruginosa* (MRPA), BAA-2108; vancomycin-resistant *Enterococcus* (VRE), 51559; multidrug-resistant *Acinetobacter baumannii* (MRAB), BAA-1605; multidrug-resistant *Enterobacter* (MRE), BAA-2468; and multidrug-resistant *Proteus mirabilis* (MRPM), BAA-2791. We maintained a stock culture of these strains of bacteria on tryptic soy agar (TSA) with 5% sheep blood (TSA II; BD GmbH, Heidelberg, Germany), and prepared fresh culture 24 hours before surgery at 37°C and in an aerobic medium (5% CO~2~). We prepared the inoculum by collecting the organisms on a cotton sterile swab, washing the cells three times in phosphate-buffered saline (PBS), and adjusting the cells to a concentration of 1 × 10^8^ colony forming units (CFU) per millilitre according to a standard curve of optical density. Each wound would be inoculated with a 1 × 10^7^ CFU bacteria in a 100 μl solution.

Rat wound infection model {#section12-2046-3758.85.BJR-2018-0280.R3}
-------------------------

To create models of wound infection, we established three modified models described in a previous study (skin defect, bone-exposed, and implant-exposed models).^[@bibr13-2046-3758.85.BJR-2018-0280.R3],[@bibr25-2046-3758.85.BJR-2018-0280.R3]^ In brief, after the backs were shaved, povidone iodine solution was applied. For the skin defect model, a full-thickness skin defect (18 mm in diameter to avoid rapid healing) was created and then inoculated with MRSA, ESBL-EC, MRPA, VRE, MRAB, MRE, and MRPM, respectively. For the bone-exposed model, the spinous process was exposed in addition to the 18 mm skin defect. Furthermore, we created the implant-exposed model by drilling one hole in the exposed spinous process, through which we inserted a 5 mm stainless wire. The rats were then randomly assigned to each treatment group. Treatment was withheld for the initial 48 hours in order to allow the wound infection to be established.

Preparation of irrigation solution {#section13-2046-3758.85.BJR-2018-0280.R3}
----------------------------------

There were five treatment groups in this study: EDTA solution, castile soap, benzalkonium chloride, bacitracin, and NS solution. The EDTA solution was made by dissolving 1 mmol of EDTA into one litre of NS. After that, the pH was adjusted to 7.4. The soap solution was prepared with 0.45% of castile soap in NS. The benzalkonium chloride solution was prepared by injecting 1.76 ml of 17% benzalkonium chloride into a litre of NS solution. The bacitracin solution was prepared by injecting 40 000 U into a litre of NS solution.

Irrigation and debridement procedures {#section14-2046-3758.85.BJR-2018-0280.R3}
-------------------------------------

Blinding was not possible as the solutions could not be masked from the investigators. The castile soap is slightly opaque and with foam; benzalkonium chloride is transparent, yellow, and with foam; bacitracin is transparent, colourless, and with foam; EDTA solution and NS are transparent, colourless, and without foam. Following irrigation and debridement of the wound, sample for bacterial culture was obtained with a cotton sterile swab and the wound was then covered by sterile dressings. We repeated the irrigation and debridement every 48 hours until the cultures obtained after previous irrigation and debridement were negative. The primary outcome was negative bacterial culture, as this has been shown to be an important indication for delayed wound closure.^[@bibr34-2046-3758.85.BJR-2018-0280.R3]^ The interval was recommended in clinical practice and adopted by previous animal studies.^[@bibr34-2046-3758.85.BJR-2018-0280.R3],[@bibr35-2046-3758.85.BJR-2018-0280.R3]^

All of the rats were given an intraperitoneal injection of 450 mg/kg chloral hydrate for general anaesthesia before the procedures. The rats then received thorough irrigation and debridement with 400 ml of the test irrigation solution using a syringe. Irrigation pressure was manually controlled. The basic principle for debridement was to establish margins of viable tissue with perfusion. After the above procedures, all of the rats in the three groups received an additional irrigation with 100 ml NS to remove residual additives or to act as a control.

Bacterial culture of wound specimens {#section15-2046-3758.85.BJR-2018-0280.R3}
------------------------------------

All specimens obtained during surgery were incubated on TSA with 5% sheep blood (TSA II; BD GmbH) for 48 hours (37°C, aerobic 5% CO~2~). A positive result was indicated by the formation of at least one colony. For further confirmation, bacterial identification was conducted with 16S ribosomal DNA sequencing by using the MicroSeq 500 microbial identification system (Thermo Fisher Scientific, Waltham, Massachusetts).

Statistical analysis {#section16-2046-3758.85.BJR-2018-0280.R3}
--------------------

Kaplan--Meier curves were computed and compared using the log-rank test. SPSS software (IBM Corp., Armonk, New York) was used for statistical analysis. Significant differences between groups for numerical and non-numerical variables were evaluated using Student's *t*-test and chi-squared test, respectively.

Results {#section17-2046-3758.85.BJR-2018-0280.R3}
=======

The direct effects of different solutions on wound healing {#section18-2046-3758.85.BJR-2018-0280.R3}
----------------------------------------------------------

We first assessed the direct effects of different solutions on wound healing by creating a 5 mm wound and irrigating the wound daily. We then compared the time needed to achieve complete healing of the wound. The results are summarized in [Table I](#table1-2046-3758.85.BJR-2018-0280.R3){ref-type="table"}. Compared with NS and EDTA solution, castile soap, benzalkonium chloride, and bacitracin showed a delay in wound healing. In addition, we repeated this daily irrigation experiment, but with 18 mm wounds. Images of the wounds are shown in [Figure 1](#fig1-2046-3758.85.BJR-2018-0280.R3){ref-type="fig"}. Wound healing was delayed following irrigation with castile soap, benzalkonium chloride, or bacitracin.

###### 

Direct effects of different irrigation solutions on wound healing

  Solution                Mean time for complete healing, days ([sd]{.smallcaps})   p-value^[\*](#table-fn1-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^
  ----------------------- --------------------------------------------------------- ------------------------------------------------------------------------------
  Normal saline           7.82 (2.13)                                               N/A
  Castile soap            10.98 (3.54)                                              \< 0.001
  Benzalkonium chloride   12.16 (3.77)                                              \< 0.001
  Bacitracin              11.92 (4.11)                                              \< 0.001
  EDTA                    7.62 (2.37)                                               0.562

Significant differences (p \< 0.05) *versus* normal saline were calculated using Student's *t*-test

N/A, not applicable; EDTA, ethylenediaminetetraacetic acid

![Images of wounds before and after two weeks. a) The original wound was created in an 18 mm size. The wounds were then irrigated daily for two weeks with: b) normal saline; c) castile soap; d) benzalkonium chloride; e) bacitracin; and f) ethylenediaminetetraacetic acid (EDTA).](bonejointres-08-189-g001){#fig1-2046-3758.85.BJR-2018-0280.R3}

EDTA irrigation in skin defect wound model {#section19-2046-3758.85.BJR-2018-0280.R3}
------------------------------------------

We compared the number of operations required to achieve a culture-negative wound among the different treatment groups. A survival analysis of culture-positive wounds over operation times was conducted. The Kaplan--Meier survival curves are shown in [Figure 2](#fig2-2046-3758.85.BJR-2018-0280.R3){ref-type="fig"}. The EDTA group showed the most superior results in the treatment of wound infections for all bacterial strains. The use of EDTA irrigation required the least number of procedures in order to produce a culture-negative wound. The mean and median number of operations to achieve culture-negative wounds are summarized in [Table II](#table2-2046-3758.85.BJR-2018-0280.R3){ref-type="table"}, along with the results of log-rank analysis of the Kaplan--Meier survival curves.

![Kaplan--Meier survival curves of skin defect wounds with positive culture of: a) methicillin-resistant *Staphylococcus aureus* (MRSA); b) extended spectrum beta-lactamase-producing *Escherichia coli* (ESBL-EC); c) multidrug-resistant *Pseudomonas aeruginosa* (MRPA); d) vancomycin-resistant *Enterococcus* (VRE); e) multidrug-resistant *Acinetobacter baumannii* (MRAB); f) multidrug-resistant *Enterobacter* (MRE); and g) multidrug-resistant *Proteus mirabilis* (MRPM). EDTA, ethylenediaminetetraacetic acid.](bonejointres-08-189-g002){#fig2-2046-3758.85.BJR-2018-0280.R3}

###### 

Operation times to achieve culture-negative wounds (skin defect wound)

  Strains / treatment                                                                          Mean operations, n ([sd]{.smallcaps})   95% CI         Median operations, n (95% CI)   p-value *versus* EDTA (log-rank)
  -------------------------------------------------------------------------------------------- --------------------------------------- -------------- ------------------------------- ----------------------------------
  **Methicillin-resistant *Staphylococcus aureus* (MRSA)**                                                                                                                            
  Normal saline                                                                                1.82 (0.12)                             1.58 to 2.06   2.00 (N/A)                      \< 0.001
  Castile soap                                                                                 1.98 (0.12)                             1.75 to 2.21   2.00 (1.62 to 2.38)             \< 0.001
  Benzalkonium chloride                                                                        2.16 (0.10)                             1.96 to 2.36   2.00 (1.73 to 2.27)             \< 0.001
  Bacitracin                                                                                   1.92 (0.11)                             1.70 to 2.14   2.00 (1.65 to 2.35)             \< 0.001
  EDTA^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^                    1.32 (0.07)                             1.19 to 1.45   1.00 (N/A)                      N/A
  **Extended spectrum beta-lactamase-producing *Escherichia coli* (ESBL-EC)**                                                                                                         
  Normal saline                                                                                2.12 (0.10)                             1.92 to 2.32   2.00 (1.73 to 2.27)             0.001
  Castile soap^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^            2.50 (0.14)                             2.22 to 2.78   2.00 (1.62 to 2.38)             \< 0.001
  Benzalkonium chloride^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^   2.52 (0.10)                             2.32 to 2.72   3.00 (2.85 to 3.15)             \< 0.001
  Bacitracin                                                                                   2.36 (0.13)                             2.11 to 2.61   3.00 (2.82 to 3.18)             \< 0.001
  EDTA^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^                    1.66 (0.08)                             1.50 to 1.82   2.00 (1.88 to 2.12)             N/A
  **Multidrug-resistant *Pseudomonas aeruginosa* (MRPA)**                                                                                                                             
  Normal saline                                                                                1.62 (0.10)                             1.42 to 1.82   1.00 (N/A)                      0.032
  Castile soap^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^            2.00 (0.13)                             1.76 to 2.24   2.00 (1.65 to 2.35)             \< 0.001
  Benzalkonium chloride^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^   2.04 (0.11)                             1.83 to 2.25   2.00 (1.71 to 2.29)             \< 0.001
  Bacitracin^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^              2.10 (0.14)                             1.83 to 2.37   2.00 (1.64 to 2.36)             \< 0.001
  EDTA^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^                    1.34 (0.08)                             1.19 to 1.49   1.00 (N/A)                      N/A
  **Vancomycin-resistant *Enterococcus* (VRE)**                                                                                                                                       
  Normal saline                                                                                1.92 (0.15)                             1.64 to 2.20   2.00 (1.78 to 2.22)             0.042
  Castile soap^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^            2.46 (0.19)                             2.10 to 2.82   2.00 (1.63 to 2.37)             \< 0.001
  Benzalkonium chloride^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^   2.42 (0.12)                             2.20 to 2.64   2.00 (1.72 to 2.28)             \< 0.001
  Bacitracin                                                                                   2.18 (0.11)                             1.97 to 2.39   2.00 (1.76 to 2.24)             \< 0.001
  EDTA^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^                    1.54 (0.07)                             1.40 to 1.68   1.00 (N/A)                      N/A
  **Multidrug-resistant *Acinetobacter baumannii* (MRAB)**                                                                                                                            
  Normal saline                                                                                1.66 (0.11)                             1.45 to 1.87   2.00 (N/A)                      0.004
  Castile soap^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^            1.98 (0.12)                             1.75 to 2.21   2.00 (1.62 to 2.38)             \< 0.001
  Benzalkonium chloride^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^   2.16 (0.10)                             1.96 to 2.36   2.00 (1.73 to 2.27)             \< 0.001
  Bacitracin^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^              2.06 (0.14)                             1.79 to 2.33   2.00 (1.65 to 2.35)             \< 0.001
  EDTA^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^                    1.30 (0.07)                             1.17 to 1.43   1.00 (N/A)                      N/A
  **Multidrug-resistant *Enterobacter* (MRE)**                                                                                                                                        
  Normal saline                                                                                2.10 (0.10)                             1.90 to 2.30   2.00 (1.78 to 2.22)             0.033
  Castile soap^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^            2.50 (0.15)                             2.21 to 2.79   2.00 (1.69 to 2.31)             \< 0.001
  Benzalkonium chloride^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^   2.72 (0.13)                             2.46 to 2.98   3.00 (2.72 to 3.28)             \< 0.001
  Bacitracin                                                                                   2.30 (0.14)                             2.04 to 2.56   2.00 (1.58 to 2.42)             0.001
  EDTA^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^                    1.78 (0.10)                             1.58 to 1.98   2.00 (1.78 to 2.22)             N/A
  **Multidrug-resistant *Proteus mirabilis* (MRPM)**                                                                                                                                  
  Normal saline                                                                                1.88 (0.13)                             1.63 to 2.13   2.00 (1.51 to 2.49)             0.031
  Castile soap                                                                                 2.12 (0.13)                             1.86 to 2.38   2.00 (1.64 to 2.36)             0.001
  Benzalkonium chloride                                                                        2.16 (0.12)                             1.93 to 2.39   2.00 (1.67 to 2.33)             \< 0.001
  Bacitracin                                                                                   2.04 (0.11)                             1.82 to 2.26   2.00 (1.70 to 2.30)             0.003
  EDTA^[\*](#table-fn3-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^                    1.50 (0.11)                             1.29 to 1.71   1.00 (N/A)                      N/A

Significant differences (p \< 0.05) *versus* normal saline were calculated using the log-rank statistic based on Kaplan--Meier curves

CI, confidence interval; EDTA, ethylenediaminetetraacetic acid; N/A, not applicable

EDTA irrigation in bone-exposed wound model {#section20-2046-3758.85.BJR-2018-0280.R3}
===========================================

The results of skin defect wound model were similarly consistent and the survival analysis of culture-positive wounds over operation times has revealed a great advantage of EDTA solution over other irrigation solutions ([Fig. 3](#fig3-2046-3758.85.BJR-2018-0280.R3){ref-type="fig"}). Likewise, the mean and median number of operations to achieve culture-negative wounds are summarized in [Table III](#table3-2046-3758.85.BJR-2018-0280.R3){ref-type="table"}, along with the Kaplan--Meier curves.

![Kaplan--Meier survival curves of bone-exposed wounds with positive culture of: a) methicillin-resistant *Staphylococcus aureus* (MRSA); b) extended spectrum beta-lactamase-producing *Escherichia coli* (ESBL-EC); c) multidrug-resistant *Pseudomonas aeruginosa* (MRPA); d) vancomycin-resistant *Enterococcus* (VRE); e) multidrug-resistant *Acinetobacter baumannii* (MRAB); f) multidrug-resistant *Enterobacter* (MRE); and g) multidrug-resistant *Proteus mirabilis* (MRPM). EDTA, ethylenediaminetetraacetic acid.](bonejointres-08-189-g003){#fig3-2046-3758.85.BJR-2018-0280.R3}

###### 

Operation times to achieve culture-negative wounds (bone-exposed wound)

  Strains / treatment                                                                          Mean operations, n ([sd]{.smallcaps})   95% CI         Median operations, n (95% CI)   p-value *versus* EDTA (log-rank)
  -------------------------------------------------------------------------------------------- --------------------------------------- -------------- ------------------------------- ----------------------------------
  **Methicillin-resistant *Staphylococcus aureus* (MRSA)**                                                                                                                            
  Normal saline                                                                                2.12 (0.16)                             1.81 to 2.43   2.00 (1.49 to 2.51)             0.022
  Castile soap^[\*](#table-fn5-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^            2.66 (0.16)                             2.35 to 2.97   3.00 (2.66 to 3.34)             \< 0.001
  Benzalkonium chloride^[\*](#table-fn5-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^   2.80 (0.15)                             2.50 to 3.10   3.00 (2.68 to 3.32)             \< 0.001
  Bacitracin^[\*](#table-fn5-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^              2.76 (0.19)                             2.39 to 3.13   3.00 (2.59 to 3.41)             \< 0.001
  EDTA^[\*](#table-fn5-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^                    1.66 (0.12)                             1.42 to 1.90   1.00 (N/A)                      N/A
  **Extended spectrum beta-lactamase-producing *Escherichia coli* (ESBL-EC)**                                                                                                         
  Normal saline                                                                                2.56 (0.14)                             2.29 to 2.83   2.00 (1.64 to 2.36)             0.001
  Castile soap                                                                                 2.62 (0.15)                             2.33 to 2.91   2.00 (1.60 to 2.40)             0.001
  Benzalkonium chloride                                                                        2.96 (0.15)                             2.68 to 3.24   3.00 (2.73 to 3.27)             \< 0.001
  Bacitracin                                                                                   2.80 (0.16)                             2.49 to 3.11   3.00 (2.73 to 3.27)             \< 0.001
  EDTA^[\*](#table-fn5-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^                    1.92 (0.12)                             1.68 to 2.16   2.00 (1.78 to 2.22)             N/A
  **Multidrug-resistant *Pseudomonas aeruginosa* (MRPA)**                                                                                                                             
  Normal saline                                                                                2.38 (0.17)                             2.04 to 2.72   2.00 (1.63 to 2.37)             0.033
  Castile soap                                                                                 2.70 (0.16)                             2.38 to 3.02   3.00 (2.62 to 3.38)             0.001
  Benzalkonium chloride                                                                        2.74 (0.16)                             2.43 to 3.05   3.00 (2.66 to 3.34)             \< 0.001
  Bacitracin^[\*](#table-fn5-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^              3.10 (0.16)                             2.78 to 3.42   3.00 (2.55 to 3.45)             \< 0.001
  EDTA^[\*](#table-fn5-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^                    1.90 (0.15)                             1.61 to 2.19   2.00 (1.69 to 2.31)             N/A
  **Vancomycin-resistant *Enterococcus* (VRE)**                                                                                                                                       
  Normal saline                                                                                2.52 (0.17)                             2.18 to 2.86   2.00 (1.60 to 2.40)             0.025
  Castile soap^[\*](#table-fn5-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^            3.24 (0.19)                             2.86 to 3.62   3.00 (2.19 to 3.81)             \< 0.001
  Benzalkonium chloride                                                                        2.80 (0.12)                             2.57 to 3.03   3.00 (2.72 to 3.28)             \< 0.001
  Bacitracin                                                                                   2.92 (0.13)                             2.66 to 3.18   3.00 (2.58 to 3.42)             \< 0.001
  EDTA^[\*](#table-fn5-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^                    2.12 (0.10)                             1.93 to 2.31   2.00 (1.76 to 2.24)             N/A
  **Multidrug-resistant *Acinetobacter baumannii* (MRAB)**                                                                                                                            
  Normal saline                                                                                2.56 (0.17)                             2.22 to 2.90   2.00 (1.62 to 2.38)             0.030
  Castile soap                                                                                 2.60 (0.17)                             2.26 to 2.94   3.00 (2.62 to 3.38)             0.020
  Benzalkonium chloride                                                                        2.76 (0.17)                             2.43 to 3.09   3.00 (2.63 to 3.37)             0.003
  Bacitracin^[\*](#table-fn5-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^              3.62 (0.17)                             3.29 to 3.95   4.00 (3.56 to 4.44)             \< 0.001
  EDTA^[\*](#table-fn5-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^                    2.06 (0.15)                             1.76 to 2.36   2.00 (1.68 to 2.32)             N/A
  **Multidrug-resistant *Enterobacter* (MRE)**                                                                                                                                        
  Normal saline                                                                                2.84 (0.18)                             2.49 to 3.19   3.00 (2.56 to 3.44)             \< 0.001
  Castile soap                                                                                 3.36 (0.18)                             3.02 to 3.70   3.00 (2.51 to 3.49)             \< 0.001
  Benzalkonium chloride                                                                        3.06 (0.16)                             2.76 to 3.36   3.00 (2.56 to 3.44)             \< 0.001
  Bacitracin^[\*](#table-fn5-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^              3.52 (0.14)                             3.25 to 3.79   3.00 (2.58 to 3.42)             \< 0.001
  EDTA^[\*](#table-fn5-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^                    2.12 (0.11)                             1.91 to 2.33   2.00 (1.76 to 2.24)             N/A
  **Multidrug-resistant *Proteus mirabilis* (MRPM)**                                                                                                                                  
  Normal saline                                                                                2.60 (0.19)                             2.23 to 2.97   3.00 (2.45 to 3.55)             0.004
  Castile soap                                                                                 3.12 (0.17)                             2.79 to 3.45   3.00 (2.47 to 3.53)             \< 0.001
  Benzalkonium chloride                                                                        2.88 (0.16)                             2.56 to 3.20   3.00 (2.63 to 3.37)             \< 0.001
  Bacitracin                                                                                   3.20 (0.15)                             2.90 to 3.50   3.00 (2.61 to 3.39)             \< 0.001
  EDTA^[\*](#table-fn5-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^                    1.98 (0.14)                             1.71 to 2.25   2.00 (1.53 to 2.47)             N/A

Significant differences (p \< 0.05) *versus* normal saline were calculated using the log-rank statistic based on Kaplan--Meier curves

CI, confidence interval; EDTA, ethylenediaminetetraacetic acid; N/A, not applicable

EDTA irrigation in implant-exposed wound model {#section21-2046-3758.85.BJR-2018-0280.R3}
----------------------------------------------

The survival analysis of culture-positive wounds over operation times was conducted and the results are shown in [Figure 4](#fig4-2046-3758.85.BJR-2018-0280.R3){ref-type="fig"}. The number of culture-positive wounds after five operations was compared and is summarized in [Table IV](#table4-2046-3758.85.BJR-2018-0280.R3){ref-type="table"}. Interestingly, only EDTA solution showed a potent effect against pathogens in implant-exposed wounds.

![Kaplan--Meier survival curves of implant-exposed wounds with positive culture of: a) methicillin-resistant *Staphylococcus aureus* (MRSA); b) extended spectrum beta-lactamase-producing *Escherichia coli* (ESBL-EC); c) multidrug-resistant *Pseudomonas aeruginosa* (MRPA); d) vancomycin-resistant *Enterococcus* (VRE); e) multidrug-resistant *Acinetobacter baumannii* (MRAB); f) multidrug-resistant *Enterobacter* (MRE); and g) multidrug-resistant *Proteus mirabilis* (MRPM). EDTA, ethylenediaminetetraacetic acid.](bonejointres-08-189-g004){#fig4-2046-3758.85.BJR-2018-0280.R3}

###### 

Wound culture after five procedures of irrigation and debridement (implant-exposed wound)

  Strains / treatment                                                           Positive wounds, n   Negative wounds, n   p-value *versus* EDTA (log-rank)
  ----------------------------------------------------------------------------- -------------------- -------------------- ----------------------------------
  **Methicillin-resistant *Staphylococcus aureus* (MRSA)**                                                                
  Normal saline                                                                 17                   3                    0.014
  Castile soap                                                                  19                   1                    0.001
  Benzalkonium chloride                                                         17                   3                    0.020
  Bacitracin                                                                    18                   2                    0.004
  EDTA^[\*](#table-fn7-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^     10                   10                   N/A
  **Extended spectrum beta-lactamase-producing *Escherichia coli* (ESBL-EC)**                                             
  Normal saline                                                                 18                   2                    \< 0.001
  Castile soap                                                                  17                   3                    \< 0.001
  Benzalkonium chloride                                                         15                   5                    0.005
  Bacitracin                                                                    16                   4                    0.002
  EDTA^[\*](#table-fn7-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^     6                    14                   N/A
  **Multidrug-resistant *Pseudomonas aeruginosa* (MRPA)**                                                                 
  Normal saline                                                                 18                   2                    0.018
  Castile soap                                                                  18                   2                    0.021
  Benzalkonium chloride                                                         19                   1                    0.005
  Bacitracin                                                                    18                   2                    0.010
  EDTA^[\*](#table-fn7-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^     11                   9                    N/A
  **Vancomycin-resistant *Enterococcus* (VRE)**                                                                           
  Normal saline                                                                 15                   5                    0.004
  Castile soap                                                                  14                   6                    0.012
  Benzalkonium chloride                                                         15                   5                    0.004
  Bacitracin                                                                    14                   6                    0.009
  EDTA^[\*](#table-fn7-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^     6                    14                   N/A
  **Multidrug-resistant *Acinetobacter baumannii* (MRAB)**                                                                
  Normal saline                                                                 17                   3                    0.028
  Castile soap                                                                  18                   2                    0.007
  Benzalkonium chloride                                                         17                   3                    0.028
  Bacitracin                                                                    17                   3                    0.014
  EDTA^[\*](#table-fn7-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^     10                   10                   N/A
  **Multidrug-resistant *Enterobacter* (MRE)**                                                                            
  Normal saline                                                                 13                   7                    0.011
  Castile soap                                                                  15                   5                    0.002
  Benzalkonium chloride                                                         15                   5                    0.001
  Bacitracin                                                                    15                   5                    0.001
  EDTA^[\*](#table-fn7-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^     5                    15                   N/A
  **Multidrug-resistant *Proteus mirabilis* (MRPM)**                                                                      
  Normal saline                                                                 17                   3                    0.002
  Castile soap                                                                  17                   3                    0.002
  Benzalkonium chloride                                                         16                   4                    0.006
  Bacitracin                                                                    15                   5                    0.014
  EDTA^[\*](#table-fn7-2046-3758.85.BJR-2018-0280.R3){ref-type="table-fn"}^     7                    13                   N/A

Significant differences (p \< 0.05) *versus* normal saline or EDTA were calculated using Pearson's chi-squared test

EDTA, ethylenediaminetetraacetic acid; N/A, not applicable

The strain of bacteria cultured from the wound was identical to the bacteria inoculated in the whole study. In other words, no contaminated bacteria were detected throughout the study.

Discussion {#section22-2046-3758.85.BJR-2018-0280.R3}
==========

Infections caused by multidrug-resistant pathogens represent a major threat worldwide.^[@bibr36-2046-3758.85.BJR-2018-0280.R3]^ Pathogens such as MRSA, ESBL-EC, MRPA, VRE, MRAB, MRE, and MRPM have been found to be the most frequent drug-resistant strains isolated from infected open fractures.^[@bibr33-2046-3758.85.BJR-2018-0280.R3]^ Although many novel antimicrobials have been established in recent decades, management of wound infection by these bacteria has been increasingly challenging.^[@bibr37-2046-3758.85.BJR-2018-0280.R3]^ Irrigation and debridement of wounds remains the cornerstone to eliminating such infections.^[@bibr38-2046-3758.85.BJR-2018-0280.R3],[@bibr39-2046-3758.85.BJR-2018-0280.R3]^

There has been a substantial number of basic and translational research projects focused on alternative irrigation solutions, but evidence from high-quality clinical trials is still scarce. As a result, the choice of irrigation solution remains controversial. A recent study demonstrated that NS as an irrigation solution was superior to surfactant-additive saline, citing concerns about toxicity and adverse effects on healing.^[@bibr14-2046-3758.85.BJR-2018-0280.R3]^ Likewise, even more wound-healing problems after bacitracin irrigation were observed.^[@bibr8-2046-3758.85.BJR-2018-0280.R3]^

We believe that this study will be an important stepping stone for the clinical translation of EDTA irrigation solution. In this study, we answered a straightforward question: "What is the effect of EDTA solution on bacteria, especially those with multidrug resistance?" We further confirmed the previous observation conducted with *S. aureus* and *E. coli*.^[@bibr25-2046-3758.85.BJR-2018-0280.R3]^ EDTA was more effective than NS solution in a rat wound model infected with seven of the most commonly isolated pathogens, which represent more than 90% of causative strains.^[@bibr33-2046-3758.85.BJR-2018-0280.R3]^ Furthermore, we showed that EDTA solution was also superior to castile soap, benzalkonium chloride, and bacitracin. PJI remains a great challenge to the orthopaedic community.^[@bibr40-2046-3758.85.BJR-2018-0280.R3]^ In this study, we showed that a substantial proportion of implant-exposed infection was eradicated after irrigation with EDTA. This result was particularly notable because of the difficulty of breaking a biofilm on an implant.^[@bibr41-2046-3758.85.BJR-2018-0280.R3]^

As with all studies that use animal models, the current work does have limitations. First, direct inoculation of swabs on agar is associated with a reduction in bacterial detection.^[@bibr42-2046-3758.85.BJR-2018-0280.R3]^ Because the detection method was identically applied in all groups, any major conclusion would not be affected. Nevertheless, this would be important for future evaluation in humans. Second, we cannot determine whether these results will make a difference in a clinical scenario. A larger model should be chosen in any future studies as it more closely mimics the clinical scenario than does a smaller animal model. Finally, if those prove similarly promising, the safety of EDTA solution should be assessed in a small-scale clinical study. It is likely that EDTA would be safe because of the long-standing usage of EDTA for medical purposes.^[@bibr43-2046-3758.85.BJR-2018-0280.R3]^ Then, perhaps a clinical study designed similarly to the fluid lavage of open wounds (FLOW) study^[@bibr14-2046-3758.85.BJR-2018-0280.R3]^ may be performed that, hopefully, would translate this important finding into clinical practice. Notably, the effective concentration might be slightly different when translating into practice among human subjects.
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